ArticleBMC nephrology2025
Development and validation of an explainable machine learning model for predicting acute kidney injury after robot-assisted partial nephrectomy: a retrospective multicenter study.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence in membranous nephropathy: transforming clinical management toward precision medicine.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRobot-assisted partial nephrectomy (RAPN) is an established, minimally invasive technique to treat patients with renal masses. The incidence of acute kidney injury (AKI) after RAPN is high and is associated with poor prognosis. This study aims to develop and validate an interpretable machine-learning model based on clinical features for individualized risk assessment of RAPN-AKI.
methodsWe retrospectively reviewed 325 patients undergoing RAPN at the Third Medical Center of PLA General Hospital (May 2022-Oct 2023) as the training dataset, and 146 from the Fifth Medical Center of PLA General Hospital (Nov 2023-Dec 2024) for external validation. Models were constructed using Boruta-selected features and eight machine learning algorithms. Performance was assessed by the area under the receiver operating characteristic curve (AUC), F1-score, accuracy, precision, calibration, and decision curve analysis (DCA). Shapley additive explanations (SHAP) interpreted feature contributions.
resultsThe incidence of AKI in internal training and external validation datasets was 24.6% and 26%, respectively. The Boruta algorithm identified duration of renal artery blockade, preoperative serum creatinine (Scr), gender, body mass index (BMI), and age as important features. Among the eight machine learning models, the Gradient Boosting Machine (GBM) model demonstrated the best and most stable predictive outcomes in the internal training dataset (AUC = 0.889) and external validation dataset (AUC = 0.779). Both the calibration curve and DCA indicated better calibration and greater net benefit. SHAP analysis revealed the contribution of important features in the following order: duration of renal artery blockade, Scr, BMI, age, and gender. Dependency plots showed that duration of renal artery blockade > 22 min, Scr > 80 µmol/L, BMI > 25 kg/m², age > 60 years, and male were significantly associated with an increased risk of AKI.
conclusionThe GBM model exhibited strong predictive performance in both internal training dataset and external validation dataset and has the potential to assist clinicians to identify the high-risk patients early, enabling timely interventions that may reduce the incidence of RAPN-AKI and improving clinical outcomes. While, the interpretable machine learning model is currently applicable only to patients with low-risk or normal preoperative renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.